Droxidopa 100 MG [Northera]
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Orthostatic Hypotension
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Trial Timeline
Feb 11, 2019 → Dec 31, 2020
NCT ID
NCT04510922About Droxidopa 100 MG [Northera]
Droxidopa 100 MG [Northera] is a approved stage product being developed by Lundbeck for Orthostatic Hypotension. The current trial status is completed. This product is registered under clinical trial identifier NCT04510922. Target conditions include Orthostatic Hypotension, Idiopathic Parkinson Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04510922 | Approved | Completed |
Competing Products
14 competing products in Orthostatic Hypotension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |
| Ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| ampreloxetine + Placebo | Theravance Biopharma | Phase 3 | 72 |
| TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |
| ampreloxetine | Theravance Biopharma | Phase 3 | 72 |
| Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin Placebo | Theravance Biopharma | Phase 1 | 28 |
| Ampreloxetine | Theravance Biopharma | Phase 1 | 28 |
| Placebo + Fipamezole | Santhera Pharmaceuticals | Phase 2 | 44 |